Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma
Technology and Health Care · 2025
DOI: 10.1177/09287329241296358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology and Health Care, 2025. Verfasst von Xinqi Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzho…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyroptosis. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Medical Scientific Research Foundation of Guangdong Province of China.
Abstract (Originalsprache)
Background
Despite advances in therapeutics, hepatocellular carcinoma (HCC) remains one of the most malignant types of digestive tract cancers with a poor prognosis. Pyroptosis is a form of programmed cell death induced by inflammatory caspases. Recent studies have identified pyroptosis, a form of programmed cell death induced by inflammatory caspases, as playing a role in tumorigenesis and cancer progression. However, the functions and mechanisms of pyroptosis in HCC are barely explored.
Methods
Gene expression and clinical data were derived from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A prognostic signature and nomogram were constructed by on differentially expressed genes and clinical data. Pathway enrichment and immune cell infiltration were further analyzed. Potential drugs to modulate the pathways were explored.
Results
In this study, a pyroptosis-related gene signature was developed and identified to be significantly correlated with the survival of HCC patients. Additionally, a nomogram on the basis of pyroptosis-related genes was constructed with distinct prognostic values. Furthermore, the pyroptosis-related gene signature might correlate with immune-related pathways and the regulation of the immune microenvironment, and several compounds (KIN001-220, TPCA-1, LY-303511, physostigmine, vemurafenib, etc.) could potentially reverse the pathogenic gene-expression patterns.
Conclusions
Our study provides evidence that pyroptosis is involved in HCC development, progression and immune microenvironment, which is promising in predicting the prognosis and developing targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China.
- Cancer Prevention Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China.
- Geriatric Critical Care Medicine, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong, 510080, China.
- Shantou University Medical College, Shantou, Guangdong, 515041, China.
- Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510080, China.
- Department of Medical Ultrasound, The First affiliated hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
ORCID-Profile: Qingfang Zhang
Förderung
- Medical Scientific Research Foundation of Guangdong Province of China
Zitieren
APA
Qiu, X., Huang, W., Liang, J., Chen, H., Sha, W., Lyu, Y., Chen, K., Yang, H., & Zhang, Q. (2025). Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma. Technology and Health Care. https://doi.org/10.1177/09287329241296358
Vancouver
Qiu X, Huang W, Liang J, Chen H, Sha W, Lyu Y, et al. Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma. Technology and Health Care. 2025. doi:10.1177/09287329241296358
BibTeX
@article{Qiu2025,
author = {Qiu, Xinqi and Huang, Wentao and Liang, Jun and Chen, Hao and Sha, Weihong and Lyu, Yanlin and Chen, Kequan and Yang, Hongwei and Zhang, Qingfang},
title = {Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma},
journal = {Technology and Health Care},
year = {2025},
doi = {10.1177/09287329241296358}
}
EUVIMED